Neurocrine Biosciences, Inc. (NBIX)
154.06
-1.86
(-1.19%)
USD |
NASDAQ |
Aug 28, 16:00
154.00
-0.06
(-0.04%)
After-Hours: 20:00
Neurocrine Biosciences Cash from Operations (Quarterly) : 78.00M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 78.00M |
| March 31, 2026 | 145.80M |
| December 31, 2025 | 388.40M |
| September 30, 2025 | 227.50M |
| June 30, 2025 | 102.00M |
| March 31, 2025 | 64.80M |
| December 31, 2024 | 242.50M |
| September 30, 2024 | 158.00M |
| June 30, 2024 | 64.60M |
| March 31, 2024 | 130.30M |
| December 31, 2023 | 123.50M |
| September 30, 2023 | 212.00M |
| June 30, 2023 | 179.60M |
| March 31, 2023 | -125.20M |
| December 31, 2022 | 143.00M |
| September 30, 2022 | 98.80M |
| June 30, 2022 | 138.10M |
| March 31, 2022 | -40.50M |
| December 31, 2021 | 4.20M |
| September 30, 2021 | 61.80M |
| June 30, 2021 | 103.20M |
| March 31, 2021 | 87.30M |
| December 31, 2020 | 88.90M |
| September 30, 2020 | -17.50M |
| June 30, 2020 | 118.90M |
| Date | Value |
|---|---|
| March 31, 2020 | 38.20M |
| December 31, 2019 | 102.55M |
| September 30, 2019 | 97.83M |
| June 30, 2019 | 64.17M |
| March 31, 2019 | -112.49M |
| December 31, 2018 | 50.45M |
| September 30, 2018 | 68.92M |
| June 30, 2018 | 20.48M |
| March 31, 2018 | -38.49M |
| December 31, 2017 | 40.58M |
| September 30, 2017 | -9.31M |
| June 30, 2017 | -48.24M |
| March 31, 2017 | -77.36M |
| December 31, 2016 | -31.62M |
| September 30, 2016 | -31.01M |
| June 30, 2016 | -14.34M |
| March 31, 2016 | -29.21M |
| December 31, 2015 | -15.20M |
| September 30, 2015 | -18.57M |
| June 30, 2015 | 13.96M |
| March 31, 2015 | -18.18M |
| December 31, 2014 | -15.31M |
| September 30, 2014 | -12.10M |
| June 30, 2014 | -9.965M |
| March 31, 2014 | -9.767M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Amarin Corp. Plc | 6.612M |
| Liquidia Corp. | 80.24M |
| Incyte Corp. | 507.66M |
| Halozyme Therapeutics, Inc. | 240.89M |
| Iovance Biotherapeutics, Inc. | -60.84M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -135.40M |
| Cash from Financing (Quarterly) | 121.80M |
| Free Cash Flow | 812.00M |
| Free Cash Flow Per Share (Quarterly) | 0.6737 |
| Free Cash Flow to Equity (Quarterly) | 74.60M |
| Free Cash Flow to Firm (Quarterly) | 72.78M |
| Free Cash Flow Yield | 5.09% |